Overview

Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease

Status:
Terminated
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn the effects of a test drug on heart rhythms, which may become life-threatening if left untreated, and to provide data to see if the drug is well tolerated and safe.
Phase:
Phase 2
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer